navitoclax + bendamustine + rituximab

Navitoclax + bendamustine + rituximab is a three-drug combination regimen under investigation for the treatment of B-cell malignancies, particularly non-Hodgkin’s lymphomas. Navitoclax is an orally bioavailable small molecule inhibitor targeting anti-apoptotic Bcl-2 family proteins (mainly Bcl-2, Bcl-xL, Bcl-w) to induce apoptosis in cancer cells. Bendamustine is an alkylating agent that causes DNA damage and cell death, and rituximab is a monoclonal antibody that targets the CD20 antigen on B cells, leading to their destruction. The combination has shown enhanced anti-tumor efficacy in preclinical lymphoma models compared to standard regimens, with a rationale based on the complementary mechanisms of apoptosis induction, DNA damage, and immune-mediated cytotoxicity[1][3].

Other names

ABT-263 + bendamustine + rituximabnavitoclax + BRnavitoclax + bendamustine + rituximab combination